State of Tennessee Department of Treasury Cuts Stock Holdings in Cencora, Inc. (NYSE:COR)

State of Tennessee Department of Treasury lowered its stake in Cencora, Inc. (NYSE:COR) by 4.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,225 shares of the company’s stock after selling 1,616 shares during the period. State of Tennessee Department of Treasury’s holdings in Cencora were worth $7,240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC raised its position in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after acquiring an additional 46 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in Cencora in the fourth quarter valued at $30,000. Kentucky Trust Co acquired a new position in Cencora in the fourth quarter valued at $33,000. Householder Group Estate & Retirement Specialist LLC grew its holdings in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co lifted its holdings in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the company’s stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now owns 315,913 shares in the company, valued at $89,027,442.53. This represents a 4.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer now directly owns 47,582 shares in the company, valued at $13,766,900.06. This trade represents a 9.46 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

Cencora stock opened at $281.89 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65. The stock has a fifty day moving average of $267.20 and a two-hundred day moving average of $248.71. The company has a market capitalization of $54.66 billion, a price-to-earnings ratio of 40.10, a PEG ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Bank of America boosted their price objective on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Wells Fargo & Company lifted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Finally, JPMorgan Chase & Co. lifted their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $284.55.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.